Literature DB >> 11293740

Endomyocardial fibrosis in children.

C L Santos1, C R Moraes, F L Santos, F Moraes, D Brindeiro Filho.   

Abstract

We describe 10 children with endomyocardial fibrosis who underwent surgical treatment between 1978 and 1999. Seven were male and 3 female, with an age range from 4 to 15 years, having a mean age of 11 years. All were in the final stage of heart failure. Three had biventricular disease, 6 had involvement of the right ventricle alone, and one had endomyocardial fibrosis confined to the left ventricle. There were 3 deaths (30%) in the postoperative period due to low cardiac output. The 7 survivors were followed up for a period ranging from 12 to 168 months, with a mean of 72 months. Two late deaths have occurred resulting from heart failure and infectious endocarditis. Five (50%) children are still alive. Two required 3 reoperations for dysfunction of the inserted valvar prosthesis. One patient is in functional Class IV, and 4 are in Class II to III, despite intensive medical treatment. It is concluded that surgery for endomyocardial fibrosis is an essentially palliative procedure and, especially in children, the results of surgical treatment leave much to be desired.

Entities:  

Mesh:

Year:  2001        PMID: 11293740     DOI: 10.1017/s1047951101000129

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  3 in total

1.  Echocardiography accurately assesses the pathological abnormalities of chronic endomyocardial fibrosis.

Authors:  A O Mocumbi; C Carrilho; P Sarathchandra; M B Ferreira; M Yacoub; M Burke
Journal:  Int J Cardiovasc Imaging       Date:  2010-11-26       Impact factor: 2.357

Review 2.  Endomyocardial fibrosis: A form of endemic restrictive cardiomyopathy.

Authors:  Ana Olga Mocumbi
Journal:  Glob Cardiol Sci Pract       Date:  2012-07-17

Review 3.  Clinical Characteristics and Treatment of Cardiomyopathies in Children.

Authors:  Jack F Price; Aamir Jeewa; Susan W Denfield
Journal:  Curr Cardiol Rev       Date:  2016
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.